<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955394</url>
  </required_header>
  <id_info>
    <org_study_id>16-1042.cc</org_study_id>
    <nct_id>NCT02955394</nct_id>
  </id_info>
  <brief_title>Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer</brief_title>
  <official_title>Randomized Phase II Trial of Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized two arm phase II study to further evaluate the efficacy of fulvestrant&#xD;
      plus enza compared to single agent fulvestrant in postmenopausal women with locally advanced&#xD;
      AR+/ER+/Her2- BC who will have local surgery after ~4 months on treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized two arm phase II study to further evaluate the efficacy of fulvestrant&#xD;
      plus enza compared to single agent fulvestrant in postmenopausal women with locally advanced&#xD;
      AR+/ER+/Her2- BC who will have local surgery after ~4 months on treatment. After consent, all&#xD;
      patients will get a tissue biopsy, and than half the patients will get fulvestrant alone&#xD;
      (standard dosing) and the other half of the patients will get fulvestrant plus enzalutamide.&#xD;
      At ~4 weeks, a biopsy will be done and therapy will be continued. Hormone therapy will&#xD;
      continue for ~4 months at which point the patients will undergo surgical resection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 21, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Document the number of patients in both treatment arms separately who have a PEPI score equal to 0 at post treatment</measure>
    <time_frame>16 Weeks</time_frame>
    <description>The preoperative endocrine prognostic index (PEPI) is a validated measure of pathologic response to endocrine therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>To determine the percentage of progression-free survival (PFS) (complete and partial response plus stable disease) for the single drug arm and combination of enzalutamide/fulvestrant arm separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate PEPI score and Progression-free survival, Clinical Benefit Rate, and Overall Response Rate</measure>
    <time_frame>16 Weeks</time_frame>
    <description>To assess the association between PEPI score and the clinical, outcomes such as PFS, ORR, clinical benefit for all subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androgen Receptor (AR) expression</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Nuclear AR expression and AR pathway expression correlation with clinical outcomes. AR expression is associated with resistance to anti-estrogen therapy. Its blockade may enhance response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>16 weeks</time_frame>
    <description>To determine the percentage of clinical benefit rate (complete and partial response plus stable disease) for the single drug arm and combination of enzalutamide/fulvestrant arm separately.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Fulvestrant Without Enzalutamide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fulvestrant With Enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC), plus160mg of Enzalutamide will be given daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>160mg of Enzalutamide will be given daily in conjunction with Fulvestrant.</description>
    <arm_group_label>Fulvestrant With Enzalutamide</arm_group_label>
    <other_name>MDV3100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)</description>
    <arm_group_label>Fulvestrant With Enzalutamide</arm_group_label>
    <arm_group_label>Fulvestrant Without Enzalutamide</arm_group_label>
    <other_name>FASLODEX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ER+ Her2- breast cancer&#xD;
&#xD;
          -  Stage at least T2 or greater&#xD;
&#xD;
          -  Planned to get local surgery&#xD;
&#xD;
          -  Postmenopausal, or if pre- or peri- menopausal, then will need to have concurrent&#xD;
             ovarian suppression.&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Not on anticoagulants&#xD;
&#xD;
          -  PS 0-2&#xD;
&#xD;
          -  Able to swallow study drug and comply with study requirements&#xD;
&#xD;
          -  ANC &gt;1000/uL, platelets &gt;75,000/uL at screening visit&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times upper limit of normal (ULN) at the screening visit unless&#xD;
             an alternate nonmalignant etiology exists (eg, Gilbert's disease)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &lt; 3 times ULN or &lt;&#xD;
             5 times ULN if patient has documented liver metastases&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  INR &lt; 1.5 times ULN, or if on warfarin, can safely transition off for biopsy&#xD;
&#xD;
          -  Willing to donate blood for research at 4 time points&#xD;
&#xD;
          -  Willing to undergo core biopsies for research at study entry and at ~4 weeks.&#xD;
&#xD;
          -  Willing to donate tissue to research from the surgical specimen&#xD;
&#xD;
          -  Written informed consent obtained prior to biopsies and blood samples&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or previously treated brain or leptomeningeal metastases&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  Prior treatment with an anti-androgen (abiraterone, ARN-509, bicalutamide,&#xD;
             enzalutamide, ODM-201, TAK-448, TAK-683, TAK-700, VT-464).&#xD;
&#xD;
          -  Systemic estrogens or androgens within 14 days before initiating therapy. Vaginal&#xD;
             estrogens are allowed if necessary for patient comfort.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>101 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony D Elias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ER+/Her2 - breast cancer</keyword>
  <keyword>Preoperative Fulvestrant</keyword>
  <keyword>Enzalutamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

